Clinical Trial Update: Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating CD19 t-haNK and NAI with Rituximab in relapsed indolent non-Hodgkin lymphoma; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• CD19 t-haNK
• NAI
• Rituximab (rituximab)

Snippet

Sponsor: ImmunityBio, Inc. | Conditions: Relapsed B-Cell Non-Hodgkin Lymphoma | Phase 2 | Status: NOT_YET_RECRUITING